We're thrilled to announce a monumental achievement that has us buzzing with excitement: SMSbiotech has, for the second consecutive year, been spotlighted in the prestigious Newsweek Investment Report - The New Era of Life Sciences!
You can find our feature in the May 23, 2025, issue of Newsweek Magazine, and trust us, you won't want to miss it. This year, the story is even more compelling.
Just a year ago, at the Biocom California Global Life Science Partnering & Investor Conference, the path to human clinical trials for our groundbreaking stem cell therapy seemed uncertain. Fast forward to today, and we're celebrating a pivotal moment: SMSbiotech's innovative therapy for Chronic Obstructive Pulmonary Disease (COPD) is officially commencing Phase 1 clinical trials in Australia!
Newsweek caught up with our Co-Founder & President, Abdulkader Rahmo, who shared this incredible update after over a decade of dedicated work. As Rahmo tells Newsweek, "The approval [to begin clinical trials] itself is a significant achievement because the cells we are working with are largely unknown to the scientific community and regulators."
This is truly a testament to the pioneering spirit and scientific rigor at SMSbiotech. Our therapy hinges on Small Mobile Stem (SMS) cells, a revolutionary approach that stimulates the body’s own stem cells rather than introducing foreign tissue. This unique mechanism holds the promise of increased safety compared to traditional stem cell therapies – a crucial benefit we're eager to confirm.
The first safety data from these trials is anticipated in just about four months, and we'll be sure to keep you updated on this exciting progress.
Ready to dive deeper into our journey and hear directly from Abdulkader Rahmo? Read the entire captivating interview now:
investmentreports.co/interview/abdulkader-rahmo-1708
This is more than just a news feature; it's a validation of our vision and a beacon of hope for millions living with COPD. Stay tuned for more updates as we embark on this transformative clinical journey!
